PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation

Strong case for the use of eplerenone in patients with mild heart failure

2011-05-23
(Press-News.org) May 22, 2011- Gothenburg, Sweden : The aldosterone antagonist eplerenone (Inspra, Pfizer) significantly reduced the development of new onset atrial fibrillation and flutter (AFF) in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC). The analysis, presented in Late Breaking Session 1, furthermore showed that the beneficial effects of eplerenone in reducing major CV events were similar in patients with and without AFF at the start of the study.

The Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure study (EMPHASIS-HF) - presented first at the American Heart Association Meeting in 2010 and published simultaneously on-line in the New England Journal of Medicine ¹ - showed that eplerenone in comparison to placebo produced a 37% reduction in the primary end point of the composite of death from cardiovascular causes or hospitalization for heart failure, a 24% reduction in cardiovascular death, and a 42% reduction in hospitalization for heart failure for patients with class 2 heart failure.

While previous studies had shown that aldosterone blockade delivered significant benefits in patients with class 3-4 heart failure (The RALES study) or in post MI patients with left ventricular dysfunction (The EPHESUS study), what had been unknown until EMPHASIS-HF was whether the benefits could be extended to the far larger population of patients with mild heart failure (class1-2). The RALES study used spironolactone, while the EPHESUS study used the newer, more selective eplerenone.

The EMPHASIS-HF trial - which involved 2737 patients from 278 centres with NYHA class 2 heart failure and ejection fractions of no more than 35% - set out to address the question of whether eplerenone was effective in patients with mild heart failure. Patients were randomized to receive eplerenone (25mg once daily, up titrated to 50 mg daily if required) or placebo in addition to recommended therapy. The trial was stopped after 21 months due to the significant benefits in the eplerenone group. In the current presentation, the investigators have re-analyzed the original data to explore the development of new onset atrial fibrillation or flutter (AFF) in patients who had no history of AFF at baseline. The study also set out to determine whether eplerenone worked as well in patients who already had AFF at baseline as those who did not.

Results at an average follow-up of two years showed that new onset AFF occurred in 25/911 (2.7%) of the patients in the group randomized to eplerenone versus 40/883 (4.5%) in the group randomized to placebo (hazard ratio (HR) 0.58 95% CI 0.35-0.96, p=0.034). The analysis also showed that the risk of cardiovascular (CV) death or hospital admission for worsening heart failure (the primary endpoint of the original study) was not significantly different in patients with and without AFF at baseline (P=0.33).

Commenting on the results study presenter Karl Swedberg, from the University of Gothenburg, Sweden, said, "This latest analysis makes an even stronger case for the use of eplerenone in patients with mild heart failure because in addition to reducing mortality it also reduces the incidence of AF. AF is a condition which both increases morbidity and complicates the care of patients with heart failure."

Use of eplerenone in patients with mild heart failure, he added, will be considered for inclusion in the ESC guidelines when they are updated at the end of 2011.

Eplerenone

Eplerenone, which has been called a "cleaner, safer" version of spironolactone, is approved for hypertension and for use in addition to optimal medical therapy early after acute MI in patients with congestive heart failure (CHF), on the basis of the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study (EPHESUS) study. It has, however, yet to be approved for patients with mild HF.

While eplerenone is available generically in the US, the drug is still under patent in Europe and Canada.

INFORMATION:

Reference

Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Eng J Med 2011: 364:11-21. Available at: http://www.nejm.org.

END



ELSE PRESS RELEASES FROM THIS DATE:

Heart Failure: Targeting the right patients for CRT-D

2011-05-23
Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial - presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC) in Late Breaking Session 1 - showed that CRT produced improvements in both synchrony and contractile function, and that the extent of this benefit relates to subsequent outcomes. The Multicentre Automatic Defibrillator ...

UBC-led team develops platform to monitor hematopoietic stem cells

2011-05-23
A Canadian research team has developed an automated microfluidic cell culture platform to monitor the growth, survival and responses of hundreds of hematopoietic stem cells (HSCs) at the single cell level. This new tool allows scientists to study multiple temporally varying culture conditions simultaneously and to gain new insights on the growth factor requirements for HSC survival. "The ability to perform massively parallel cultures of single non-adherent mammalian cells will provide new avenues to explore complex biological questions," says Véronique Lecault, lead ...

Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis

2011-05-23
A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor (TNF), can also suppress aspects of inflammation. The researchers say the identification of the mechanism of how this occurs could potentially lead to new treatments for diseases such as rheumatoid arthritis. The study was published May 22 online in advance of publication in the journal Nature Immunology. "Prior to this study, TNF has long been known as a potent pro-inflammatory cytokine, but if you look carefully through ...

Adevarul Chooses Locklizard PDF DRM Security to Secure Ebooks

2011-05-23
Adevarul, Romania's premier integrated multimedia business publishing magazines such as OK!, Forbes, etc. chooses LockLizard Safeguard Enterprise PDF DRM to secure ebooks in their new ebook shop, www.adevarulshop.ro. Adevarul had been looking to provide digital products and take a leading position in the rapidly developing ebook marketplace, but concerns over piracy and associated loss of revenue had prevented them from pursuing this avenue further. Enter LockLizard with their PDF DRM software - a DRM solution for secure ebooks in PDF format. LockLizard PDF DRM has been ...

Scientists find new drug target in breast cancer

2011-05-23
Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine. In a mouse model of breast cancer, blocking production of the protein using genetic techniques caused tumours to shrink. The scientists are now looking for new drugs which could achieve a similar effect. Breast cancer is the most common cancer in the UK, affecting about 46,000 women each year. More than two thirds of breast tumours contain oestrogen receptors, meaning that ...

Gulf currents primed bacteria to degrade oil spill

2011-05-23
A new computer model of the Gulf of Mexico in the period after the oil spill provides insights into how underwater currents may have primed marine microorganisms to degrade the oil. "It is called dynamic auto-inoculation. Parcels of water move over the ruptured well, picking up hydrocarbons. When these parcels come back around and cross back over the well, the bacteria have already been activated, are more abundant than before, and degrade hydrocarbons far more quickly," says David Valentine of the University of California, Santa Barbara, speaking today at the 111th ...

Page 1 Solutions Launches New Company Website Design and Logo

Page 1 Solutions Launches New Company Website Design and Logo
2011-05-23
Page 1 Solutions, a Colorado-based Internet marketing and website design agency, just launched a new website design and new logo for the company on May 17th, 2011. Page 1 offers Web marketing services to attorneys, dentists, plastic surgeons, and ophthalmologists across the U.S. and Canada. It has been three years since Page 1 has had a new website design and the timing was perfect for the new site to go live. It was launched right before the American Academy of Cosmetic Dentistry (AACD) meeting in Boston, MA, where Page 1 is exhibiting. Spring and summer are busy travel ...

The dance of the cells: A minuet or a mosh?

2011-05-23
Boston, MA – The physical forces that guide how cells migrate—how they manage to get from place to place in a coordinated fashion inside the living body— are poorly understood. Scientists at the Harvard School of Public Health (HSPH) and the Institute for Bioengineering of Catalonia (IBEC) have, for the first time, devised a way to measure these forces during collective cellular migration. Their surprising conclusion is that the cells fight it out, each pushing and pulling on its neighbors in a chaotic dance, yet together moving cooperatively toward their intended direction. The ...

A direct path for understanding and treating brittle bones

2011-05-23
Boston - A study by researchers at Children's Hospital Boston and collaborators at other institutions has provided new insights into the means by which bone cells produce new bone in response to mechanical stresses, such as exercise. Their findings lay a path for developing new strategies for treating diseases characterized by low bone density, such as osteoporosis in adults and osteogenesis imperfecta in children. The research team, led by Matthew Warman, MD, of the Orthopedic Research Laboratories (ORL) in the Department of Orthopedic Surgery at Children's Hospital ...

A study opens the possibility of developing a preventive vaccine against HIV/AIDS

2011-05-23
The HIV epidemic is the largest in the world and represents one of the most serious public health problems, according to data from the World Health Organization (WHO). Only 30% of the more than 10 million patients in need have the access to the antiretroviral treatment. The total number of infected people exceeds 30 million and there are about 3 million new infections per year. The best hope for reducing the incidence of AIDS (Acquired Immune Deficiency Syndrome) is a preventive vaccine. The most effective preventive vaccines act by inducing a response based on neutralizing ...

LAST 30 PRESS RELEASES:

‘Molecular shield’ placed in the nose may soon treat common hay fever trigger

Beetles under climate stress lay larger male eggs: Wolbachia infection drives adaptive reproduction strategy in response to rising temperature and CO₂

Groundbreaking quantum study puts wave-particle duality to work

Weekly injection could be life changing for Parkinson’s patients

Toxic metals linked to impaired growth in infants in Guatemala

Being consistently physically active in adulthood linked to 30–40% lower risk of death

Nerve pain drug gabapentin linked to increased dementia, cognitive impairment risks

Children’s social care involvement common to nearly third of UK mums who died during perinatal period

‘Support, not judgement’: Study explores links between children’s social care involvement and maternal deaths

Ethnic minority and poorer children more likely to die in intensive care

Major progress in fertility preservation after treatment for cancer of the lymphatic system

Fewer complications after additional ultrasound in pregnant women who feel less fetal movement

Environmental impact of common pesticides seriously underestimated

The Milky Way could be teeming with more satellite galaxies than previously thought

New study reveals surprising reproductive secrets of a cricket-hunting parasitoid fly

Media Tip Sheet: Symposia at ESA2025

NSF CAREER Award will power UVA engineer’s research to improve drug purification

Tiny parasitoid flies show how early-life competition shapes adult success

New coating for glass promises energy-saving windows

Green spaces boost children’s cognitive skills and strengthen family well-being

Ancient trees dying faster than expected in Eastern Oregon

Study findings help hone precision of proven CVD risk tool

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

Introducing BioEmu: A generative AI Model that enables high-speed and accurate prediction of protein structural ensembles

Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans

New research shows how tropical plants manage rival insect tenants by giving them separate ‘flats’

Condo-style living helps keep the peace inside these ant plants

Climate change action could dramatically limit rising UK heatwave deaths

Annual heat-related deaths projected to increase significantly due to climate and population change

Researchers discover new way cells protect themselves from damage

[Press-News.org] EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation
Strong case for the use of eplerenone in patients with mild heart failure